載入中
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
前收盤價
US$19.60
−US$0.34 · -1.71%
盤後
US$19.60
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
日內區間
目前US$19.60
52週區間
目前US$19.60
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.03億 USD | 8007.7萬 USD | 6251.8萬 USD | 4300.8萬 USD | 2063.6萬 USD |
| 銷售、一般及管理費用 | 2983.4萬 USD | 2410萬 USD | 1742.7萬 USD | 1591.9萬 USD | 565.2萬 USD |
| 營業費用 | 1.33億 USD | 1.04億 USD | 7994.5萬 USD | 5892.7萬 USD | 2628.8萬 USD |
| 利息收入 | 1281.5萬 USD | 1769.6萬 USD | 1081.1萬 USD | 365.2萬 USD | 1.3萬 USD |
| 折舊和攤銷 | 54.6萬 USD | 51.9萬 USD | 35.7萬 USD | 29.6萬 USD | 14萬 USD |
| 營業利益 | −1.33億 USD | −1.04億 USD | −7994.5萬 USD | −5892.7萬 USD | −2628.8萬 USD |
| 淨利 | −1.2億 USD | −8648.1萬 USD | −6913.4萬 USD | −5532.5萬 USD | −2629.4萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$45.17
上漲空間 130.46%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
